Boehringer Ingelheim’s Bonanza Month |
Abstract
pdf
|
Business Review Editor |
|
Therapy Focus: Hypoxia-Selective Agents as Anticancer Drugs |
Abstract
pdf
|
Business Review Editor |
|
Deal Making Spotlights on Big Pharma |
Abstract
pdf
|
Business Review Editor |
|
Astellas Enters into Yet Another Agreement |
Abstract
pdf
|
Business Review Editor |
|
Abraxis and AstraZeneca Exchange Agreements |
Abstract
pdf
|
Business Review Editor |
|
Chelsea Augments its Pipeline |
Abstract
pdf
|
Business Review Editor |
|
Immunomedics Relights its Therapeutic Potential |
Abstract
pdf
|
Business Review Editor |
|
IPOs: Still the Exit Strategy of Choice? |
Abstract
|
Business Review Editor |
|
AstraZeneca to Acquire Cambridge Antibody Technology |
Abstract
pdf
|
Business Review Editor |
|
Kos to Market SkyePharma’s Flutiform™ |
Abstract
pdf
|
Business Review Editor |
|